Clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Tasci
Ilker
I
D000924:Anticholesteremic Agents / Q000494:pharmacology; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D003920:Diabetes Mellitus / Q000503:physiopathology; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D017127:Glycation End Products, Advanced / Q000097:blood*; D006538:Heptanoic Acids / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000150:complications; D011758:Pyrroles / Q000494:pharmacology
D000924:Anticholesteremic Agents; D015415:Biomarkers; D017127:Glycation End Products, Advanced; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin